All In Biotech

Drug Trial Radar · NCT07092215

Mechanisms of Pain Hypersensitivity in a Human Skin Inflammation Model

Mechanisms of Pain Hypersensitivity in a Human Skin Inflammation Model - A Double-blind, Randomized, Placebo-controlled Crossover Study

Last checked: Nov 19, 2026Latest source record: Jul 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Jun 17, 2025

Primary completion

Jul 11, 2025

Study completion Jul 11, 2025

Sponsor

Lead sponsor
Stefan HeberAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main goal of this double-blind, randomized, placebo-controlled crossover study is to understand the molecular mechanisms of inflammation-induced increased pain sensitivity (hyperalgesia). These mechanisms are studied using a recently established human model of skin inflammation that mimics aspects of skin infection. A localized inflammatory response in the skin of healthy volunteers is elicited by locally injecting a small, safe dose of Lipopolysaccharide (LPS), a major component of gram-negative bacteria. The study addresses three key research questions: * Role of RAGE: To investigate if certain inflammatory effects of LPS, which contribute to hyperalgesia, are mediated by a signaling pathway involving the RAGE receptor. * Pain Sensitization: To examine how skin inflammation affects pain caused by acidic stimuli, and to differentiate this from purely mechanical pain. * Role of TRPV1: To determine if the contribution of the TRPV1 ion channel to acid-induced pain is different in inflamed skin. Participants will undergo an experimental session 4.5 hours after LPS injection to measure skin blood flow (using laser speckle imaging), mechanical pain sensitivity (using specialized tweezers), and pain induced by injecting a solution, of which the pH is gradually decreasing (acid-induced pain). The study has minimal risks due to the small, safe doses of substances used ('microdosing') and aims to lay the groundwork for developing new treatments for inflammatory pain conditions.

Conditions

  • Pain

Interventions

  • Synthetic interstitial fluid (SIF) / SIF neutral pHDrug

    Intradermal injection of SIF at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4)

  • Synthetic interstitial fluid (SIF) / SIF acidic pHDrug

    Intradermal injection of SIF at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to pH 5.7)

  • Synthetic interstitial fluid (SIF) / SIF acidic pH + BCTC 1 µMDrug

    Intradermal injection of SIF at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to pH 5.7), containing BCTC 1 µM

  • LPS 5 ng / SIF neutral pHDrug

    Intradermal injection of LPS 5 ng at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4)

  • LPS 5 ng / SIF acidic pHDrug

    Intradermal injection of LPS 5 ng at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to pH 5.7)

  • LPS 5 ng / SIF acidic pH + BCTC 1 µMDrug

    Intradermal injection of LPS 5 ng at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to pH 5.7), containing BCTC 1 µM

  • LPS 5 ng + Azeliragon 100 µM / SIF neutral pHDrug

    Intradermal injection of LPS 5 ng + Azeliragon 100 µM at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4)

  • LPS 5 ng + Azeliragon 100 µM / SIF acidic pHDrug

    Intradermal injection of LPS 5 ng + Azeliragon 100 µM at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to 5.7)

  • LPS 5 ng + Resatorvid 10 µM / SIF neutral pHDrug

    Intradermal injection of LPS 5 ng + Resatorvid 10 µM at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4)

  • LPS 5 ng + Resatorvid 10 µM / SIF acidic pHDrug

    Intradermal injection of LPS 5 ng + Resatorvid 10 µM at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4 to pH 5.7)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Skin PerfusionTime frame: 4.5h after the (non-)LPS injections

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical University of Vienna

    Vienna, State of Vienna, Austria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.